Intravitreous Ranibizumab Cost-Effective for Some With Proliferative Diabetic Retinopathy

At 5 years, intravitreous ranibizumab therapy for proliferative diabetic retinopathy (DR) appears to be cost-effective relative to panretinal photocoagulation (PRP), but only in eyes with vision-impairing center-involved diabetic macular edema (CI-DME), according to new findings reported in Reuters Health.

“These cost-effectiveness analyses may be relevant to decisions made on a broader, public-health level,” Adam R. Glassman of Jaeb Center for Health Research, in Tampa, Florida told Reuters Health by email.

Read the full article.